These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37146128)

  • 1. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy.
    Wang-Bishop L; Kimmel BR; Ngwa VM; Madden MZ; Baljon JJ; Florian DC; Hanna A; Pastora LE; Sheehy TL; Kwiatkowski AJ; Wehbe M; Wen X; Becker KW; Garland KM; Schulman JA; Shae D; Edwards D; Wolf MM; Delapp R; Christov PP; Beckermann KE; Balko JM; Rathmell WK; Rathmell JC; Chen J; Wilson JT
    Sci Immunol; 2023 May; 8(83):eadd1153. PubMed ID: 37146128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional STING-Activating Mn
    Zhou M; Wang X; Lin S; Cheng Y; Zhao S; Lin J; Fang Z; Lou Z; Qin L; Wei H
    Adv Healthc Mater; 2020 Jul; 9(13):e2000064. PubMed ID: 32484320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors.
    Xian S; Chen X; Ren S; Chen X; Wang H
    Cancer Res; 2024 Sep; 84(18):3044-3057. PubMed ID: 38990727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade.
    Wang M; Huang Y; Chen M; Wang W; Wu F; Zhong T; Chen X; Wang F; Li Y; Yu J; Wu M; Chen D
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37620043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
    Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
    ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomineralized MnO
    Deng Z; Xi M; Zhang C; Wu X; Li Q; Wang C; Fang H; Sun G; Zhang Y; Yang G; Liu Z
    ACS Nano; 2023 Mar; 17(5):4495-4506. PubMed ID: 36848115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Activation of cGAS for Cancer Immunotherapy.
    Garland KM; Rosch JC; Carson CS; Wang-Bishop L; Hanna A; Sevimli S; Van Kaer C; Balko JM; Ascano M; Wilson JT
    Front Immunol; 2021; 12():753472. PubMed ID: 34899704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STING-activating cyclic dinucleotide-manganese nanoparticles evoke robust immunity against acute myeloid leukemia.
    Aikins ME; Sun X; Dobson H; Zhou X; Xu Y; Lei YL; Moon JJ
    J Control Release; 2024 Apr; 368():768-779. PubMed ID: 38492861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A manganese-phenolic network platform amplifying STING activation to potentiate MRI guided cancer chemo-/chemodynamic/immune therapy.
    Pang X; Fu C; Chen J; Su M; Wei R; Wang Y; Lin W; Wei X; Jiang X; Yang X; Yang H; Wang J; Yang R
    Biomater Sci; 2023 May; 11(11):3840-3850. PubMed ID: 37074080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy.
    Zheng H; Guo B; Qiu X; Xia Y; Qu Y; Cheng L; Meng F; Zhong Z
    Bioact Mater; 2022 Oct; 16():1-11. PubMed ID: 35386324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy.
    Wilson J; Kimmel B; Arora K; Chada N; Bharti V; Kwiatkowski A; Finklestein J; Hanna A; Arner E; Sheehy T; Pastora L; Yang J; Pagendarm H; Stone P; Taylor B; Hubert L; Gibson-Corley K; May J; McLean J; Rathmell J; Richmond A; Rathmell W; Balko J; Fingleton B; Hargrove-Wiley E
    Res Sq; 2024 May; ():. PubMed ID: 38766114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
    Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.
    Go EJ; Yang H; Park W; Lee SJ; Han JH; Kong SJ; Lee WS; Han DK; Chon HJ; Kim C
    Small; 2023 Oct; 19(43):e2300544. PubMed ID: 37381624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration.
    Sultan H; Wu J; Fesenkova VI; Fan AE; Addis D; Salazar AM; Celis E
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.